OE33 is a human cancer cell line derived from esophageal adenocarcinoma, one of the fastest-rising cancer types in Western countries over the past several decades. Established in 1996 from a patient with stage IIa Barrett’s-associated cancer, it has become one of the most widely used laboratory models for studying how this disease develops, resists treatment, and interacts with the immune system. Its popularity stems from a combination of features: it carries several of the genetic alterations commonly found in patient tumors, it grows reliably in culture, and it has been genomically characterized in enough detail to serve as a reference point for drug and radiation studies.
Where OE33 Came From
Esophageal adenocarcinoma typically arises through a well-recognized progression. Chronic acid reflux damages the normal squamous lining of the esophagus, which can be replaced by a glandular lining called Barrett’s esophagus. In a fraction of patients, this Barrett’s tissue progresses through increasing degrees of abnormality and eventually becomes cancerous. OE33 was derived from a tumor at an early-to-intermediate stage of this process, specifically from a pathological stage IIa Barrett’s-associated adenocarcinoma.1Scientific Reports. Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1 When it was first established, the cells were characterized by karyotyping and cell surface antigen analysis, but no molecular comparison to the original patient tumor was reported at that time. That gap has since been partially filled by whole-genome sequencing efforts that verified OE33 against original patient material.2PubMed Central. Whole-genome sequencing of nine esophageal adenocarcinoma cell lines
Under the microscope and in growth assays, OE33 cells behave as epithelial-like cells, which is consistent with their origin from glandular tissue.3PubMed Central. Improved xenograft efficiency of esophageal adenocarcinoma cell lines through in vivo selection When grown in three-dimensional tissue constructs that mimic the layered structure of the esophagus, they express E-cadherin and Keratin 8, two markers typical of the type of glandular cells found in Barrett’s-related tumors.4PubMed Central. Activin a signaling regulates cell invasion and proliferation in esophageal adenocarcinoma This epithelial character is one reason OE33 is often chosen over more mesenchymal-like esophageal cancer cell lines: it better represents the starting tissue type that most patients’ tumors resemble at diagnosis.
Key Genetic Features
Two genetic features of OE33 make it especially relevant to current clinical questions in esophageal adenocarcinoma: its TP53 status and its HER2 amplification.
The TP53 gene encodes p53, a protein that normally acts as a brake on uncontrolled cell growth. In OE33, TP53 is mutated and functionally inactive.5PubMed Central. Occurrence of multipolar mitoses and association with Aurora-A/-B kinases and p53 mutations in aneuploid esophageal carcinoma cells This matters because the vast majority of esophageal adenocarcinomas in patients also carry TP53 mutations, so a cell line without this feature would be a poor stand-in.6Clinical Cancer Research. Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy Loss of p53 contributes to the genomic instability that characterizes these tumors, including wide-ranging copy number changes that affect how genes are expressed.
OE33 also has high-level amplification and strong overexpression of HER2, a receptor that sits on the cell surface and drives growth signaling.7PLoS ONE. Trastuzumab Mediated T-Cell Response against HER-2/Neu Overexpressing Esophageal Adenocarcinoma Depends on Intact Antigen Processing Machinery About one in five esophageal adenocarcinomas in patients overexpress HER2, and these patients are often candidates for targeted therapy with drugs like trastuzumab. OE33 has become a go-to model for studying HER2-targeted treatments precisely because its HER2 status mirrors that subgroup of patients.
Beyond HER2, OE33 also carries amplification of MET, another growth-driving receptor. This dual amplification creates an interesting therapeutic challenge: when researchers tested the MET-targeting drug foretinib on OE33, the cells showed reduced sensitivity compared with what might be expected, because HER2 appeared to provide an alternative survival signal. Blocking only one receptor was not enough; the other picked up the slack.8PubMed. HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells This kind of crosstalk between signaling pathways is a major reason why targeted drugs often fail in the clinic, and OE33 provides a concrete model for studying how to overcome it.
Whole-genome sequencing has cataloged a broader set of alterations in OE33, including point mutations, small insertions and deletions, and extensive copy number changes.2PubMed Central. Whole-genome sequencing of nine esophageal adenocarcinoma cell lines Among those copy number changes are alterations in genes encoding kinetochore components, parts of the machinery that segregates chromosomes during cell division. Disruption of this machinery helps explain why OE33 cells, like many esophageal adenocarcinoma tumors, are highly aneuploid, carrying abnormal numbers of chromosomes.9University of Cambridge Apollo Repository. Investigating the origins of polyploidy in Barretts oesophagus and oesophageal adenocarcinoma
Modeling the Barrett’s-to-Cancer Progression
One of the more creative uses of OE33 has been as an endpoint in multi-cell-line systems designed to mimic the stepwise progression from normal esophagus to Barrett’s metaplasia to cancer. Researchers have assembled panels of cell lines representing each stage: normal esophageal squamous cells, Barrett’s metaplasia, dysplasia, and finally adenocarcinoma lines including OE33 and its sibling line OE19.10PubMed Central. In-depth characterization of the Wnt-signaling/β-catenin pathway in an in vitro model of Barrett’s sequence By comparing molecular signaling across these stages, scientists can track how pathways change as the disease progresses, something that is difficult to do in patients because tissue from every stage is rarely available from the same individual.
How faithfully do these lab models reflect what happens in actual patients? One study tackled that question directly by comparing gene expression profiles from clinical databases with an in vitro model that combined a Barrett’s cell line with OE33 and OE19. The combination captured roughly 65% or more of the molecular alterations observed during Barrett’s development and progression to adenocarcinoma in patient tissues.11PubMed Central. Barrett’s Metaplasia Progression towards Esophageal Adenocarcinoma: An Attempt to Select a Panel of Molecular Sensors and to Reflect Clinical Alterations by Experimental Models That is not a perfect recapitulation, but it is high enough to make the model genuinely useful for screening hypotheses before testing them in more complex and expensive animal models or clinical trials. The remaining 35% represents molecular complexity that simple cell cultures on plastic dishes cannot reproduce, including contributions from surrounding tissues, immune cells, and the physical architecture of the esophagus.
Studying Drug Resistance
Esophageal adenocarcinoma is notoriously difficult to treat with chemotherapy, and one reason is that tumors often develop resistance to drugs like cisplatin that are used in standard regimens. OE33 has been used to create laboratory models of this resistance by exposing cells to gradually increasing doses of cisplatin over time, producing a cisplatin-resistant daughter line called OE33 Cis R alongside the parental cisplatin-sensitive line OE33 Cis P.
An unexpected finding from this model was that cisplatin-resistant OE33 cells actually became more sensitive to other treatment modalities. OE33 Cis R cells were significantly more vulnerable to both radiation and the chemotherapy drug 5-fluorouracil compared to the parental cells.12PubMed Central. Characterisation of an Isogenic Model of Cisplatin Resistance in Oesophageal Adenocarcinoma Cells If this pattern holds in patients, it suggests that tumors that stop responding to cisplatin might be newly vulnerable to other treatments rather than broadly resistant to everything, a clinically actionable insight.
Targeted drug studies have also used OE33 to understand how HER2-positive esophageal adenocarcinomas respond to agents like lapatinib, which blocks HER2 and its related receptor EGFR. OE33 was found to form mainly HER2 homodimers on its surface, and lapatinib was effective in these strongly HER2-positive cells. Anti-HER2 antibodies also triggered antibody-dependent cellular cytotoxicity when OE33 cells were cultured with immune cells.13PubMed. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer The implication is that the way HER2 molecules pair up on the cell surface influences which drugs work best, and OE33 provides a model where one common pairing pattern can be studied in detail.
Radiation Resistance and Metabolism
Radiation is a central component of treatment for esophageal cancer, yet many tumors resist it. Several research groups have used OE33 to build radioresistant models by repeatedly irradiating cells at clinically relevant doses. In one well-documented protocol, OE33 cells received 25 cycles of 2 Gy radiation, accumulating a total dose of 50 Gy, with rest periods between doses to allow recovery. The surviving cells, called OE33R, were then compared to mock-irradiated parental cells (OE33P) maintained under identical conditions.14Cell Death & Disease. AKR1C3 enhances radioresistance in esophageal adenocarcinoma via inhibiting ferroptosis through suppressing TRIM21-mediated ubiquitination of HSPA5 These isogenic pairs, genetically identical except for the changes acquired during radiation exposure, are powerful tools for identifying exactly what changes when a tumor cell learns to survive radiation.15PubMed. Generation and Characterization of an Isogenic Cell Line Model of Radioresistant Esophageal Adenocarcinoma
One finding from these models is that radioresistant OE33R cells are more metabolically active than their sensitive counterparts. OE33R cells showed significantly higher baseline oxygen consumption, indicating more active mitochondria, which correlated with higher levels of intracellular energy stores. Interestingly, the contribution of glycolysis to total energy production was similar in resistant and sensitive cells; the difference was mainly on the mitochondrial side.16PLoS ONE. Altered Mitochondrial Function and Energy Metabolism Is Associated with a Radioresistant Phenotype in Oesophageal Adenocarcinoma This suggests that radioresistant cells may rely on ramped-up mitochondrial metabolism to fuel the DNA repair and stress-response machinery that helps them survive radiation damage.
Separate from radiation-induced metabolic changes, OE33 has also been used to study how obesity, a major risk factor for esophageal adenocarcinoma, influences tumor cell behavior at the metabolic level. When OE33 cells were exposed to conditioned media from the fat tissue of obese esophageal cancer patients, they shifted toward glycolysis and became more sensitive to a glycolytic inhibitor.17PubMed Central. Excess visceral adiposity induces alterations in mitochondrial function and energy metabolism in esophageal adenocarcinoma The metabolic signature of the obese-patient fat tissue showed altered patterns of sugars and amino acids, hinting at a mechanism by which excess body fat might reshape how the tumor fuels itself. Given that obesity is one of the strongest epidemiological risk factors for this cancer, this line of research has real clinical weight.
Radiation studies using OE33 have also revealed that not all cells within the line respond equally to treatment. A subpopulation of OE33 cells marked by the surface profile CD44-positive/CD24-negative showed higher proliferation rates, better ability to form spheres in culture (a measure of stem-like behavior), and greater resistance to radiation compared to unsorted or CD44-positive/CD24-positive cells.18PubMed. Prediction of response to radiotherapy in the treatment of esophageal cancer using stem cell markers The idea that a small population of stem-like cells within a tumor can survive treatment and repopulate the tumor afterward is widely discussed across cancer types, and OE33 provides a concrete system for investigating it in esophageal adenocarcinoma.
Immune Evasion and Immunotherapy Research
A growing area of OE33 research involves understanding how the tumor interacts with the immune system, particularly T cells. Esophageal adenocarcinoma has historically not responded as well to immunotherapy as some other cancer types, and co-culture experiments with OE33 are helping to explain why.
When immune cells from esophageal adenocarcinoma patients were cultured alongside OE33 cells, the tumor cells actively suppressed the T cells. T cells co-cultured with OE33 upregulated LAG-3, an inhibitory checkpoint molecule, and downregulated CD27, a co-stimulatory marker needed for robust immune activation. When those immune cells were placed under low-oxygen or nutrient-deprived conditions mimicking the interior of a tumor, the picture worsened: the secreted factors from stressed immune cells caused OE33 to upregulate PD-L1 and PD-L2 on its surface, effectively strengthening the cell’s immune-evasion armor.19PubMed Central. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy This creates a vicious cycle: the hostile tumor environment weakens immune cells, and the weakened immune cells inadvertently help the tumor become even harder to attack.
More encouragingly, combination immunotherapy has shown promise against OE33 in these lab settings. When T cells were treated with both nivolumab and ipilimumab, two checkpoint inhibitor drugs that block different immune brakes, the dual treatment significantly enhanced killing of OE33 cells compared to untreated T cells. Even more striking, when the tumor cells had first been exposed to the FLOT chemotherapy regimen commonly used in esophageal cancer, the immune-cell killing was amplified further.20Translational Oncology. Cooperation between chemotherapy and immune checkpoint blockade to enhance anti-tumour T cell immunity in oesophageal adenocarcinoma The finding that standard chemotherapy might prime tumor cells to become more vulnerable to immunotherapy is one of the more clinically exciting insights to emerge from OE33-based experiments, and it aligns with a broader trend across oncology toward combining these two treatment modalities.
Epigenetic Studies
Beyond its DNA sequence, OE33 has been used to study epigenetic regulation, the chemical modifications layered on top of genes that determine whether they are turned on or off. One line of investigation involves a small regulatory RNA called miR-4715-3p, which normally acts as a brake on the cancer-promoting gene AURKA. In OE33, the region encoding this RNA is heavily methylated, meaning chemical tags silence its expression, allowing AURKA to run unchecked. When researchers treated OE33 with a demethylating agent, the RNA’s expression rose significantly while AURKA levels dropped, confirming that the silencing was epigenetically controlled rather than caused by a mutation in the DNA itself.21Scientific Reports. Epigenetic regulation of AURKA by miR-4715-3p in upper gastrointestinal cancers This type of finding is relevant because epigenetic changes are, in principle, reversible, whereas DNA mutations are not. Drugs that strip away abnormal methylation could theoretically reactivate silenced tumor-suppressor pathways. OE33 serves as a proof-of-concept system for testing that idea.
Limitations Worth Knowing About
For all its usefulness, OE33 has limitations that researchers are well aware of and that anyone interpreting studies based on it should keep in mind. The most fundamental is that it is a single cell line grown on plastic. Cells in culture lose the three-dimensional architecture, blood supply, immune milieu, and neighboring tissue interactions that exist in a living tumor. The 65% concordance figure with clinical gene expression profiles mentioned earlier is a useful benchmark: it means roughly a third of the molecular picture is missing from the model.
The original characterization gap is also worth noting. When OE33 was first established, no analysis of the primary tumor was presented alongside the cell line, so the research community could not directly assess whether the mutations carried by the cultured cells faithfully represented the tumor they came from.1Scientific Reports. Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1 Later whole-genome sequencing efforts verified the cells against original patient material, partly closing this gap, but the concern illustrates a broader issue with older cancer cell lines that were established before modern authentication standards existed.
Another consideration is that OE33 represents just one molecular subtype of esophageal adenocarcinoma. Its combination of HER2 amplification, MET amplification, and TP53 loss overlaps with a subset of patient tumors but not all of them. Tumors without HER2 overexpression, for example, may behave quite differently, and findings from OE33 should not be assumed to generalize to the entire disease. Researchers working in this area typically use panels of multiple cell lines, pairing OE33 with lines like FLO-1, SK-GT-4, and OE19, each carrying different constellations of mutations, to get a broader view. OE33’s role is usually as the HER2-positive, epithelial-like representative in such panels, complemented by lines with other profiles to cover the heterogeneity of the disease.